JPWO2021074157A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021074157A5 JPWO2021074157A5 JP2022522361A JP2022522361A JPWO2021074157A5 JP WO2021074157 A5 JPWO2021074157 A5 JP WO2021074157A5 JP 2022522361 A JP2022522361 A JP 2022522361A JP 2022522361 A JP2022522361 A JP 2022522361A JP WO2021074157 A5 JPWO2021074157 A5 JP WO2021074157A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- ilt
- binds
- nkg2a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962914595P | 2019-10-14 | 2019-10-14 | |
| US62/914,595 | 2019-10-14 | ||
| PCT/EP2020/078792 WO2021074157A1 (fr) | 2019-10-14 | 2020-10-13 | Traitement du cancer avec des inhibiteurs d'ilt-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553927A JP2022553927A (ja) | 2022-12-27 |
| JPWO2021074157A5 true JPWO2021074157A5 (fr) | 2023-10-18 |
Family
ID=72944114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522361A Withdrawn JP2022553927A (ja) | 2019-10-14 | 2020-10-13 | Ｉｌｔ－２阻害剤での癌の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240294634A1 (fr) |
| EP (1) | EP4045535A1 (fr) |
| JP (1) | JP2022553927A (fr) |
| CN (1) | CN114901689A (fr) |
| WO (1) | WO2021074157A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328931A1 (en) | 2019-08-12 | 2022-03-24 | Biond Biologics Ltd. | Antibodies against ILT2 and use thereof |
| MX2023001776A (es) | 2020-08-12 | 2023-03-10 | Biond Biologics Ltd | Anticuerpos contra ilt2 y uso de los mismos. |
| WO2024140820A1 (fr) * | 2022-12-28 | 2024-07-04 | 浙江博锐生物制药有限公司 | Anticorps anti-nkg2a et son utilisation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3659625A1 (fr) * | 2014-10-23 | 2020-06-03 | Innate Pharma | Traitement de cancers à l'aide d'agents anti-nkg2a |
| PT3405495T (pt) * | 2016-01-21 | 2021-05-14 | Innate Pharma | Neutralização de vias inibidoras em linfócitos |
| WO2019144052A1 (fr) * | 2018-01-18 | 2019-07-25 | Adanate, Inc. | Anticorps anti-lilrb et leurs utilisations |
| US20220025045A1 (en) * | 2018-12-26 | 2022-01-27 | Innate Pharma | Compounds and methods for treatment of head and neck cancer |
-
2020
- 2020-10-13 WO PCT/EP2020/078792 patent/WO2021074157A1/fr active Application Filing
- 2020-10-13 EP EP20793296.3A patent/EP4045535A1/fr active Pending
- 2020-10-13 CN CN202080069390.1A patent/CN114901689A/zh active Pending
- 2020-10-13 JP JP2022522361A patent/JP2022553927A/ja not_active Withdrawn
- 2020-10-13 US US17/768,484 patent/US20240294634A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Evgin et al. | Oncolytic virus-derived type I interferon restricts CAR T cell therapy | |
| Lind et al. | Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances | |
| Pesce et al. | PD/1-PD-Ls checkpoint: insight on the potential role of NK cells | |
| Isidori et al. | Immunotherapy in acute myeloid leukemia: where we stand | |
| Freedman et al. | Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies | |
| Liu et al. | Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes | |
| JP2018522887A5 (fr) | ||
| Antonia et al. | Immunotherapy: beyond anti–PD-1 and anti–PD-L1 therapies | |
| JP2019519245A5 (fr) | ||
| Kojima et al. | Immunotherapy for esophageal squamous cell carcinoma | |
| JP2020503891A5 (fr) | ||
| JP2016527286A5 (fr) | ||
| Yang et al. | Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells | |
| Roy et al. | Blockade of PD-1 and LAG-3 immune checkpoints combined with vaccination restores the function of antiviral tissue-resident CD8+ TRM cells and reduces ocular herpes simplex infection and disease in HLA transgenic rabbits | |
| JP7388798B2 (ja) | Ｓｕｖ３９ｈ１を欠損する免疫細胞 | |
| JP2016530889A5 (fr) | ||
| Dozier et al. | Immunotherapy for malignant pleural mesothelioma: current status and future directions | |
| CN111712517B (zh) | 靶向il-1rap的car-t细胞及它们的用途 | |
| Corgnac et al. | CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses | |
| JP2019501973A5 (fr) | ||
| Khan et al. | Evolving concepts: immunity in oncology from targets to treatments | |
| Semmrich et al. | Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’tumors | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| Grenier et al. | Combining adoptive cell therapy with cytomegalovirus-based vaccine is protective against solid skin tumors | |
| Ascierto et al. | Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) |